Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2013

ChemAxon Boosts Boehringer Ingelheim toward Next-Gen Cheminformatics

  • Boehringer Ingelheim has chosen ChemAxon’s chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners. ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties, and reactions. The goal is to help streamline the progression from drug discovery to clinical candidate. ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability, and future development roadmap.

    Last year, Eisai licensed ChemAxon’s JChem Cartridge for Oracle product. The database storage and search technology is being used by Eisai for the management of chemical structure information generated in discovery processes in Eisai’s global R&D organization.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »